Literature DB >> 9445195

Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production.

R H Laeng1, H J Altermatt, B W Scheithauer, D R Zimmermann.   

Abstract

BACKGROUND: Amyloidomas or localized tumor-like amyloid deposits rarely affect the nervous system. To the authors' knowledge, no comprehensive studies on central and peripheral nervous system amyloidomas have been published. The amyloid subtype of amyloidomas of the nervous system only recently was characterized and almost invariably was found to be of amyloid light chain (AL) lambda type. The nature of the plasma cell population responsible for AL amyloid production has not been investigated further.
METHODS: The current analysis included the clinical findings, neuroimaging characteristics, and pathology of seven amyloidomas (four cerebral and three involving peripheral nerves). All were subjected to histochemical staining (Congo red, thioflavine S) and to immunohistochemical study using primary antibodies detecting serum amyloid component P, serum amyloid protein A (SAA), transthyretin, beta2 microglobulin (beta2m), and free immunoglobulin (Ig) light chain. For the detection of mRNA of light chain Ig, fluorescein-conjugated kappa and lambda mRNA oligonucleotide probes were used. For the assessment of B-cell clonality, polymerase chain reaction (PCR) was applied on extracted DNA from two cases using VH FRIII and JH primers. Two cases were assessed ultrastructurally.
RESULTS: All amyloidomas were organ restricted and unrelated to systemic amyloidosis. The clinical symptoms of the cerebral lesions were nonspecific, whereas neurologic deficits were noted in the distribution of the involved peripheral nerves. Cerebral deposits, either solitary or multiple, were associated spatially with the choroid plexus and secondarily extended into white matter. All peripheral nerve amyloidomas involved the gasserian ganglion of the trigeminal nerve. Imaging by computed tomography and magnetic resonance imaging scans revealed hyperdense and contrast-enhancing mass lesions unassociated with significant edema. Immunohistochemically, the amyloid was present in the interstitium and within the walls of the intralesional vessels, was invariably of AL lambda subtype, and was negative for free Ig kappa light chains, SAA, transthyretin, and beta2m. Plasma cells along the perivascular sheaths and occasionally squeezed between amyloid masses showed no cytologic atypia. In situ hybridization for Ig light chain mRNA reflected a massive preponderance of lambda-producing cells. PCR revealed monoclonal rearrangement of the heavy chain Ig gene.
CONCLUSIONS: The results of the current study provide strong support for the concept that amyloidomas of the nervous system are neoplasms of an AL lambda-producing B-cell clone capable of terminal differentiation. Nevertheless, all seven patients lacked clinical evidence of an aggressive or systemic lymphoplasmacytic neoplasm. Unlike plasmacytomas, the relatively indolent course of most nervous system amyloidomas is reminiscent of the similarly indolent biologic behavior of extranodal, low grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445195     DOI: 10.1002/(sici)1097-0142(19980115)82:2<375::aid-cncr18>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Imaging of focal amyloid depositions in the head, neck, and spine: amyloidoma.

Authors:  Hemant Parmar; T Rath; M Castillo; D Gandhi
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

2.  MRI of pathology-proven peripheral nerve amyloidosis.

Authors:  Gavin A McKenzie; Stephen M Broski; Benjamin M Howe; Robert J Spinner; Kimberly K Amrami; Angela Dispenzieri; Michael D Ringler
Journal:  Skeletal Radiol       Date:  2016-10-12       Impact factor: 2.199

3.  Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma.

Authors:  Adam J Loavenbruck; Vinay Chaudhry; Steven R Zeldenrust; Robert J Spinner; Jason D Theis; Christopher J Klein
Journal:  Muscle Nerve       Date:  2012-11       Impact factor: 3.217

4.  Monoclonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: detection with polymerase chain reaction.

Authors:  T Miyamoto; T Kobayashi; M Makiyama; S Kitada; M Fujishima; Y Hagari; M Mihara
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

5.  Primary amyloidosis presenting as upper limb multiple mononeuropathies.

Authors:  Jennifer A Tracy; Peter J Dyck; P James B Dyck
Journal:  Muscle Nerve       Date:  2010-05       Impact factor: 3.217

6.  Trigeminal amyloidoma: case report and review of the literature.

Authors:  Oren N Gottfried; Steven Chin; H Christian Davidson; William T Couldwell
Journal:  Skull Base       Date:  2007-09

7.  Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?

Authors:  Adam J Loavenbruck; Wolfgang Singer; Michelle L Mauermann; Paola Sandroni; P James B Dyck; Morie Gertz; Christopher J Klein; Phillip A Low
Journal:  Ann Neurol       Date:  2016-07-25       Impact factor: 10.422

Review 8.  Localized AL amyloidosis: a suicidal neoplasm?

Authors:  Per Westermark
Journal:  Ups J Med Sci       Date:  2012-02-15       Impact factor: 2.384

9.  Inter-laboratory validation of PCR-based HPV detection in pathology specimens.

Authors:  Iver Petersen; Christiane Schewe; Karsten Schlüns; Manfred Dietel; Norbert Speich; Christoph Schmitt; Magdolna Bollmann; Karl Sotlar; Burkhard Bültmann; Maria T Dours-Zimmermann; Barbara Padberg; Dieter R Zimmermann
Journal:  Virchows Arch       Date:  2007-07-10       Impact factor: 4.535

10.  Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and "aggregoma": an update on classification and diagnosis.

Authors:  Marco Skardelly; Georgios Pantazis; Sotirios Bisdas; Guenther C Feigl; Martin U Schuhmann; Marcos S Tatagiba; Rainer Ritz
Journal:  BMC Neurol       Date:  2013-08-15       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.